Graph Therapeutics (Graph Tx) raises a 3.1M euro pre-seed round to improve improve the lives of patients with immune-mediated diseases through Al-driven precision medicine.
Graph Tx is based on the veteran techbio team that previously pioneered AI-driven precision oncology in Allcyte, which was acquired by Exscientia for 60M USD. The team now reunites to tackle the critical and complex challenges of inflammatory and immunological diseases.
Graph uses perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies & biomarkers for immune-driven diseases.
